Clinical trial of 3,4-diaminopyridine(3,4-DAP) for the Lambert-Eaton myasthenic syndrome

Next Previous
Trial Profile

Clinical trial of 3,4-diaminopyridine(3,4-DAP) for the Lambert-Eaton myasthenic syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Lambert-Eaton myasthenic syndrome
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top